Viewing Study NCT00292760


Ignite Creation Date: 2025-12-25 @ 2:11 AM
Ignite Modification Date: 2025-12-26 @ 12:38 AM
Study NCT ID: NCT00292760
Status: COMPLETED
Last Update Posted: 2009-12-16
First Post: 2006-02-15
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
Sponsor: Royal Marsden NHS Foundation Trust
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module